In the BioHarmony Drug Report Database

"Preview" Icon

Macitentan

Opsumit (macitentan) is a small molecule pharmaceutical. Macitentan was first approved as Opsumit on 2013-10-18. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension. The pharmaceutical is active against endothelin-1 receptor. In addition, it is known to target endothelin receptor type B. Opsumit’s patents are valid until 2029-04-18 (FDA).

 

Trade Name

 

Opsumit
 

Common Name

 

macitentan
 

ChEMBL ID

 

CHEMBL2103873
 

Indication

 

pulmonary hypertension
 

Drug Class

 

Endothelin receptor antagonists

Image (chem structure or protein)

Macitentan structure rendering